Hims & Hers Health (NYSE:HIMS) Shares Gap Up Following Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares gapped up before the market opened on Monday after Needham & Company LLC upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $15.74, but opened at $23.22. Needham & Company LLC now has a $30.00 price target on the stock. Hims & Hers Health shares last traded at $22.19, with a volume of 65,862,502 shares changing hands.

A number of other research firms also recently commented on HIMS. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Bank of America reduced their price target on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, February 9th. Truist Financial reaffirmed a “hold” rating and issued a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, BTIG Research downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $29.77.

Insider Transactions at Hims & Hers Health

In related news, insider Irene Becklund sold 8,411 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider directly owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. The trade was a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 80,463 shares of company stock worth $2,846,696. Insiders own 17.71% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk ends lawsuit and agrees to distribute Wegovy/Ozempic via Hims — removes a recent existential legal threat and opens direct access to high‑margin, in‑demand GLP‑1 drugs on Hims’ platform, which could materially lift revenues and gross margins if commercial terms are solid. Read More.
• Positive Sentiment: Management/legal risk perceived as lower after the truce and public statements from Novo; media and analyst attention is framing this as a strategic pivot into branded GLP‑1 distribution. Read More.
• Positive Sentiment: Needham upgraded HIMS to Buy with a $30 price target, signaling some sell‑side support for upside from the deal and helping momentum. Read More.
• Neutral Sentiment: Extremely high short interest (reports cite ~81M shares short; a large % of the float) has made HIMS susceptible to a short squeeze — this can extend rallies quickly, but it’s driven by positioning rather than fundamentals. Read More.
• Neutral Sentiment: Heavy media coverage and volume are creating elevated short‑term volatility; further price moves will depend on the deal’s commercial details (pricing, exclusivity, timing) that aren’t fully public. Read More.
• Negative Sentiment: Analysts and commentators warn the rally may be unsustainable if the move is driven primarily by squeeze dynamics rather than durable fundamentals; sharp reversals are possible once positioning unwinds. Read More.
• Negative Sentiment: A securities‑litigation firm, Kahn Swick & Foti, has initiated an investigation into Hims’ officers and directors related to the prior Novo dispute — an active probe could prolong legal/PR risk even after the settlement. Read More.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $26,000. Quent Capital LLC acquired a new position in Hims & Hers Health during the third quarter worth $28,000. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at $28,000. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the third quarter valued at about $28,000. Finally, Bogart Wealth LLC increased its stake in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 40.5%

The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The business’s 50 day moving average price is $24.51 and its 200 day moving average price is $37.89. The firm has a market cap of $5.04 billion, a PE ratio of 43.37, a PEG ratio of 3.01 and a beta of 2.56.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the previous year, the firm posted $0.11 EPS. Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has approved a stock buyback program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.